Tevogen TVGN
NASDAQ TVGN
$7.29 -0.05 (-0.68%)
At close: Sep 10, 2026 · 4:00 PM EDT

Tevogen (TVGN) Total Non-Current Liabilities (2021 - 2026)

Tevogen's (TVGN) quarterly Total Non-Current Liabilities came in at -$814.0 million in Q2 2026, down 330630.29% on a YoY basis from N/an in Q2 2025, and down 106761.36% quarter-over-quarter from $763163.0 in Q1 2026.

Analysis

Tevogen (TVGN) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends

Tevogen (TVGN) has reported Total Non-Current Liabilities for 6 consecutive years, with -$814.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Total Non-Current Liabilities fell 330630.29% year-over-year to -$814.0 million; the trailing twelve-month figure through Jun 2026 stood at -$814.0 million (down 330630.29% YoY), and the FY2025 full-year result was $12.6 million, up 25.3% from the prior year.
  • Total Non-Current Liabilities slipped to -$814.0 million in Q2 2026 per TVGN's latest filing, from $763163.0 in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $99.9 million in Q4 2023 and bottomed at -$814.0 million in Q2 2026.
  • Historically, Total Non-Current Liabilities has averaged -$31.7 million across 5 years, with a median of $11.5 million in 2024.
  • The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities soared 563.8% in 2023, then sank 330630.29% in 2026.
  • Over 5 years, Total Non-Current Liabilities stood at $15.1 million in 2022, then jumped by 563.8% to $99.9 million in 2023, then plunged by 89.94% to $10.0 million in 2024, then rose by 25.3% to $12.6 million in 2025, then slumped by 6564.81% to -$814.0 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered -$814.0 million, $763163.0, and $12.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Krystal Biotech 10.21 Bn 9.37 Bn 112.79 Mn 134.44 Mn
2 CRISPR Therapeutics AG 5.04 Bn 5.04 Bn - 898.00 Mn
3 Iovance Biotherapeutics 3.65 Bn 3.36 Bn 55.72 Mn 72.64 Mn
4 Legend Biotech 3.54 Bn 2.57 Bn 251.50 Mn 117.70 Mn
5 uniQure 2.95 Bn 2.95 Bn 5.49 Mn 577.71 Mn
6 Beam Therapeutics 2.55 Bn 2.55 Bn - 313.33 Mn
7 Precigen 2.39 Bn 2.39 Bn 52.17 Mn 126.64 Mn
8 Sarepta Therapeutics 2.16 Bn 1.37 Bn 251.87 Mn 1.66 Bn
9 Vericel 1.93 Bn 1.77 Bn 56.40 Mn 130.91 Mn
10 Tevogen 27.76 Mn 27.76 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -814.00 Mn
Mar 31, 2026 763,163.00
Dec 31, 2025 12.59 Mn
Sep 30, 2025 -1.68 Mn
Jun 30, 2025 -246,122.00
Mar 31, 2025 -2.21 Mn
Dec 31, 2024 10.05 Mn
Sep 30, 2024 10.47 Mn
Jun 30, 2024 -3.06 Mn
Mar 31, 2024 9.11 Mn
Dec 31, 2023 99.91 Mn
Sep 30, 2023 16.53 Mn
Jun 30, 2023 16.22 Mn
Mar 31, 2023 15.37 Mn
Dec 31, 2022 15.05 Mn
Sep 30, 2022 14.98 Mn
Jun 30, 2022 14.96 Mn
Mar 31, 2022 14.88 Mn
Dec 31, 2021 14.76 Mn